

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 22, 2004  
-----

BECTON, DICKINSON AND COMPANY

-----  
(Exact name of registrant as specified in its charter)

<TABLE>		
<S>	<C>	<C>
New Jersey	001-4802	22-0760120
-----	-----	-----
(State or other juris- diction of incorporation)	(Commission File Number)	(IRS Employer Iden- tification Number)
1 Becton Drive, Franklin Lakes, New Jersey		07417-1880
-----	-----	-----
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code (201) 847-6800  
-----

N/A

-----  
(Former name or former addresses if changed since last report.)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 - Press release dated July 22, 2004  
announcing financial results for the third fiscal quarter  
ended June 30, 2004, which is furnished pursuant  
to Item 12.

Item 12. Results of Operations and Financial Condition.

On July 22, 2004, the Company issued a press release announcing  
its financial results for the third fiscal quarter ended June  
30, 2004. A copy of the press release is furnished as Exhibit 99.1  
to this Current Report and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Paranicas

-----

Dean J. Paranicas  
Vice President,  
Corporate Secretary and  
Public Policy

Date: July 22, 2004

INDEX TO EXHIBITS

-----

<TABLE>  
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued July 22, 2004

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

Contact:

- -----

Patricia A. Spinella, Investor Relations - 201-847-5453  
Colleen T. White, Corporate Communications - 201-847-5369

BD ANNOUNCES RESULTS FOR FISCAL THIRD QUARTER

Franklin Lakes, NJ (July 22, 2004) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of \$1.258 billion for the fiscal third quarter ended June 30, 2004, representing an increase of 8 percent from the same period a year ago. At constant foreign exchange rates, revenues increased 5 percent. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro.

Diluted earnings per share and net income for the quarter were 41 cents and \$109 million, respectively. As announced in our July 2, 2004 press release, third quarter results included a pre-tax charge of \$100 million relating to the agreement with Retractable Technologies, Inc. to settle its lawsuit against BD. This charge reduced net income by \$63 million and diluted earnings per share by 24 cents.

For the third quarter of fiscal 2003, reported diluted earnings per share and net income were 49 cents and \$130 million, respectively. Included in these prior period results was a charge of \$34 million related to the write-down of certain intangible assets and inventory in the BD Biosciences segment. This charge reduced diluted earnings per share by 8 cents and net income by \$20 million. Excluding the charge of 8 cents, pro forma diluted earnings per share for the third quarter of fiscal 2003 were 57 cents.

"These results reflect another solid quarter of revenue and earnings growth, fueled especially by sales of safety-engineered products and immunocytometry instruments and reagents, along with improved gross profit margins," stated Edward J. Ludwig, Chairman, President and Chief Executive Officer. "In addition, having settled the lawsuit, we can now concentrate all of our efforts on driving revenue growth through innovation focused on products that have a higher benefit to patients, healthcare workers and researchers."

Q3 Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$683 million, representing an increase of 5 percent over the prior year period. BD Medical revenues reflect the continued conversion in the U.S. to safety-engineered products, which had sales of \$110 million, as compared with \$101 million in the prior year's quarter. The BD Medical sales growth rate was constrained by comparison to a particularly strong quarter in fiscal 2003.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$374 million, representing an increase of 11 percent over the prior year period. Revenue growth of 12 percent in the Preanalytical Systems unit of the segment reflects the continued conversion in the U.S. to safety-engineered devices which had sales of \$80 million, compared with \$66 million in the prior year's quarter. Revenue growth of 9 percent in the Diagnostic Systems unit of the segment included solid worldwide sales of its molecular diagnostic platform, BD ProbeTec™ ET.

In the BD Biosciences segment, worldwide revenues for the quarter were \$201 million, representing an increase of 12 percent over the prior year period. Instrument revenue growth was driven by sales of the recently launched BD FACSCanto™ and BD FACSAria™ analyzers and continued strong performance of the BD FACSAria™ cell sorter. Sales of flow cytometry reagents were also strong in both the clinical and the research markets.

Q3 Geographic Results

Third quarter revenues in the U.S. of \$617 million represented an increase of 6 percent over the prior year period. Revenues outside the U.S. of \$641 million represented an increase of 10 percent over the prior year period, or 4 percent at constant foreign exchange rates.

Nine-Month Results

For the nine-month period ended June 30, 2004, reported revenues were \$3.728

billion, an 11 percent increase over the same period a year ago, or 6 percent at constant foreign exchange rates. Reported diluted earnings per share for the nine-month period were \$1.51. Included in the nine-month results of fiscal 2004 was a first quarter charge of 11 cents related to certain actions taken in connection with our blood glucose monitoring products and a third quarter charge of 24 cents related to the previously mentioned litigation settlement. Excluding both these charges, pro forma diluted earnings per share for the nine-month period were \$1.86. For the same nine-month period in fiscal 2003, reported diluted earnings per share were \$1.46. Excluding the aforementioned charge of 8 cents related to the write-down of certain intangible assets and inventory in the BD Biosciences segment, pro forma diluted earnings per share for the nine-month period in fiscal 2003 were \$1.54.

#### Fiscal 4Q 2004 Outlook

For the fourth quarter, the Company expects reported diluted earnings per share will increase about 10 percent.

#### Conference Call Information

A conference call regarding BD's third quarter results and its expectations for the fourth quarter will be broadcast live on BD's website [www.bd.com/investors](http://www.bd.com/investors) at 10:00 a.m. (ET) Thursday, July 22, 2004. A replay of the conference call will be available on the investors page of BD's website or at 1-866-419-5473 (domestic) and 1-203-369-0771 (international) through July 29, 2004.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of

medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of \$4.528 billion.

\*\*\*

This press release, including the section entitled "Fiscal 4Q 2004 Outlook," contains certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; changes in BD's sales volume and product mix; BD's ability to achieve its cost savings objectives; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

Three Months Ended June 30,

	2004	2003	% Change
<S>	<C>	<C>	<C>
REVENUES	\$1,257,755	\$1,165,369	7.9
Cost of products sold	624,212	622,387	0.3
Selling and administrative	338,052	308,475	9.6
Research and development	60,800	60,042	1.3
Litigation settlement	100,000	-	NM
TOTAL OPERATING COSTS AND EXPENSES	1,123,064	990,904	13.3
OPERATING INCOME	134,691	174,465	(22.8)
Interest expense, net	(4,128)	(9,658)	(57.3)
Other expense, net	(701)	(2,036)	(65.6)
INCOME BEFORE INCOME TAXES	129,862	162,771	(20.2)
Income tax provision	20,466	32,753	(37.5)
NET INCOME	\$ 109,396	\$ 130,018	(15.9)
EARNINGS PER SHARE			
Basic	\$ 0.43	\$ 0.51	(15.7)
Diluted	\$ 0.41	\$ 0.49	(16.3)
AVERAGE SHARES OUTSTANDING			
Basic	252,433	255,038	
Diluted	264,336	265,088	

</TABLE>

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY  
RECONCILIATION TO PRO FORMA AMOUNTS  
Three Months Ended June 30,  
(Unaudited)

<TABLE>  
<CAPTION>

	2004		
	As Reported	Litigation Settlement**	Excluding Charges
<S>	<C>	<C>	<C>
Diluted EPS	\$0.41	\$0.24	\$0.65

</TABLE>

<TABLE>  
<CAPTION>

	2003		
	As Reported	Non-cash Charges***	Excluding Charges
<S>	<C>	<C>	<C>
Diluted EPS	\$0.49	\$0.08	\$0.57

</TABLE>

\*\* Relates to the fiscal 2004 charge associated with the settlement of litigation with Retractable Technologies, Inc.

\*\*\* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Three Months Ended June 30,  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	2004		
	As Reported	Litigation Settlement**	Excluding Charges
<S>	<C>	<C>	<C>
Operating Income	\$134,691	\$100,000	\$234,691
as a % of revenues	10.7%		18.7%
Net Income	109,396	63,000	172,396
as a % of revenues	8.7%		13.7%

</TABLE>

<TABLE>  
<CAPTION>

	2003		
	As Reported	Non-cash Charges***	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$542,982	\$ 34,231	\$577,213
as a % of revenues	46.6%		49.5%
Operating Income	174,465	34,231	208,696
as a % of revenues	15.0%		17.9%
Net Income	130,018	20,196	150,214
as a % of revenues	11.2%		12.9%

</TABLE>

\*\* Relates to the fiscal 2004 charge associated with the settlement of litigation with Retractable Technologies, Inc.

\*\*\* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

Page 2

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	Nine Months Ended June 30,		
	2004	2003	% Change
<S>	<C>	<C>	<C>
REVENUES	\$3,727,809	\$3,351,058	11.2

Cost of products sold	1,903,145	1,750,854	8.7
Selling and administrative	1,006,300	891,454	12.9
Research and development	184,007	179,921	2.3
Litigation settlement	100,000	-	NM
-----			
TOTAL OPERATING COSTS AND EXPENSES	3,193,452	2,822,229	13.2
-----			
OPERATING INCOME	534,357	528,829	1.0
Interest expense, net	(21,018)	(26,944)	(22.0)
Other (expense) income, net	(3,865)	(3,799)	1.7
-----			
INCOME BEFORE INCOME TAXES	509,474	498,086	2.3
Income tax provision	109,516	112,390	(2.6)
-----			
NET INCOME	\$ 399,958	\$ 385,696	3.7
-----			
EARNINGS PER SHARE			
Basic	\$ 1.58	\$ 1.51	4.6
Diluted	\$ 1.51	\$ 1.46	3.4
AVERAGE SHARES OUTSTANDING			
Basic	252,617	255,008	
Diluted	264,008	263,995	

</TABLE>

NM - Not Meaningful

Page 3

BECTON DICKINSON AND COMPANY  
RECONCILIATION TO PRO FORMA AMOUNTS  
Nine Months Ended June 30,  
(Unaudited)

<TABLE>  
<CAPTION>

	2004			
	As Reported	BGM Charges*	Litigation Settlement**	Excluding Charges
<S>	<C>	<C>	<C>	<C>
Diluted EPS	\$1.51	\$0.11	\$0.24	\$1.86

</TABLE>

<TABLE>  
<CAPTION>

	2003		
	As Reported	Non-cash Charges***	Excluding Charges
<S>	<C>	<C>	<C>
Diluted EPS	\$1.46	\$0.08	\$1.54

</TABLE>

\* Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.

\*\* Relates to the fiscal 2004 charge associated with the settlement of litigation with Retractable Technologies, Inc.

\*\*\* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 Nine Months Ended June 30,  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

	2004			
	As Reported	BGM Charges*	Litigation Settlement**	Excluding Charges
<S>	<C>	<C>	<C>	<C>
Gross Profit as a % of revenues	\$1,824,664 48.9%	\$45,024	\$ -	\$1,869,688 50.2%
Operating Income as a % of revenues	534,357 14.3%	45,024	100,000	679,381 18.2%
Net Income as a % of revenues	399,958 10.7%	27,915	63,000	490,873 13.2%

<TABLE>  
 <CAPTION>

	2003		
	As Reported	Non-cash Charges***	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit as a % of revenues	\$1,600,204 47.8%	\$34,231	\$1,634,435 48.8%
Operating Income as a % of revenues	528,829 15.8%	34,231	563,060 16.8%
Net Income as a % of revenues	385,696 11.5%	20,196	405,892 12.1%

\* Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.

\*\* Relates to the fiscal 2004 charge associated with the settlement of litigation with Retractable Technologies, Inc.

\*\*\* Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

	Three Months Ended June 30,		
	2004	2003	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
United States	\$ 316,312	\$ 306,036	3.4
International	366,333	342,392	7.0



TOTAL	\$ 682,645	\$ 648,428	5.3
-----			
BD DIAGNOSTICS			
United States	\$ 206,842	\$ 190,888	8.4
International	167,353	147,295	13.6
-----			
TOTAL	\$ 374,195	\$ 338,183	10.6
-----			
BD BIOSCIENCES			
United States	\$ 93,456	\$ 86,164	8.5
International	107,459	92,594	16.1
-----			
TOTAL	\$ 200,915	\$ 178,758	12.4
-----			
TOTAL REVENUES			
United States	\$ 616,610	\$ 583,088	5.7
International	641,145	582,281	10.1
-----			
TOTAL	\$1,257,755	\$1,165,369	7.9
-----			

</TABLE>

Page 5

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	Nine Months Ended June 30,		
	2004	2003	% Change
	<C>	<C>	<C>
-----			
<S>			
BD MEDICAL			
United States	\$ 940,747	\$ 895,256	5.1
International	1,051,407	926,628	13.5
-----			
TOTAL	\$1,992,154	\$1,821,884	9.3
-----			
BD DIAGNOSTICS			
United States	\$ 631,178	\$ 588,626	7.2
International	526,837	438,011	20.3
-----			
TOTAL	\$1,158,015	\$1,026,637	12.8
-----			
BD BIOSCIENCES			
United States	\$ 255,802	\$ 234,046	9.3
International	321,838	268,491	19.9
-----			
TOTAL	\$ 577,640	\$ 502,537	14.9
-----			
TOTAL REVENUES			
United States	\$1,827,727	\$1,717,928	6.4
International	1,900,082	1,633,130	16.3
-----			
TOTAL	\$3,727,809	\$3,351,058	11.2
-----			

</TABLE>

Page 6

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30,  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	United States		
	2004	2003	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
Medical Surgical Systems	\$200,407	\$190,831	5.0
Diabetes Care	85,693	81,329	5.4
Pharmaceutical Systems	24,382	28,029	(13.0)
Ophthalmic Systems	5,830	5,847	(0.3)
TOTAL	\$316,312	\$306,036	3.4
BD DIAGNOSTICS			
Preanalytical Systems	\$113,305	\$102,869	10.1
Diagnostic Systems	93,537	88,019	6.3
TOTAL	\$206,842	\$190,888	8.4
BD BIOSCIENCES			
Discovery Labware	\$ 26,353	\$ 25,053	5.2
Immunocytometry Systems	39,871	34,960	14.0
Clontech	8,076	8,091	(0.2)
Pharmingen	19,156	18,060	6.1
TOTAL	\$ 93,456	\$ 86,164	8.5
TOTAL UNITED STATES	\$616,610	\$583,088	5.7

</TABLE>

Page 7

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	International				
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$188,824	\$179,543	5.2	0.2	5.0
Diabetes Care	62,299	55,785	11.7	5.2	6.5
Pharmaceutical Systems	106,829	99,319	7.6	0.4	7.2
Ophthalmic Systems	8,381	7,745	8.2	(0.1)	8.3
TOTAL	\$366,333	\$342,392	7.0	1.0	5.9
BD DIAGNOSTICS					
Preanalytical Systems	\$ 88,640	\$ 77,503	14.4	7.8	6.6
Diagnostic Systems	78,713	69,792	12.8	6.2	6.6
TOTAL	\$167,353	\$147,295	13.6	7.0	6.6

BD BIOSCIENCES					
Discovery Labware	\$ 21,397	\$ 21,596	(0.9)	(7.4)	6.5
Immunocytometry Systems	62,237	49,121	26.7	20.0	6.7
Clontech	6,858	7,720	(11.2)	(17.1)	5.9
Pharmingen	16,967	14,157	19.8	11.6	8.3
-----					
TOTAL	\$107,459	\$ 92,594	16.1	9.2	6.8
-----					
TOTAL INTERNATIONAL	\$641,145	\$582,281	10.1	3.9	6.3
-----					

</TABLE>

Page 8

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	Total				
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<S>	<C>	<C>	<C>	<C>	<C>
-----					
BD MEDICAL					
Medical Surgical Systems	\$ 389,231	\$ 370,374	5.1	2.7	2.4
Diabetes Care	147,992	137,114	7.9	5.3	2.6
Pharmaceutical Systems	131,211	127,348	3.0	(2.6)	5.6
Ophthalmic Systems	14,211	13,592	4.6	(0.2)	4.7
-----					
TOTAL	\$ 682,645	\$ 648,428	5.3	2.1	3.1
-----					
BD DIAGNOSTICS					
Preanalytical Systems	\$ 201,945	\$ 180,372	12.0	9.1	2.8
Diagnostic Systems	172,250	157,811	9.1	6.2	2.9
-----					
TOTAL	\$ 374,195	\$ 338,183	10.6	7.8	2.9
-----					
BD BIOSCIENCES					
Discovery Labware	\$ 47,750	\$ 46,649	2.4	(0.7)	3.0
Immunocytometry Systems	102,108	84,081	21.4	17.5	3.9
Clontech	14,934	15,811	(5.5)	(8.5)	2.9
Pharmingen	36,123	32,217	12.1	8.5	3.6
-----					
TOTAL	\$ 200,915	\$ 178,758	12.4	8.9	3.5
-----					
TOTAL REVENUES	\$1,257,755	\$1,165,369	7.9	4.8	3.1
-----					

</TABLE>

Page 9

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Nine Months Ended June 30,  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

United States			
	2004	2003	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
Medical Surgical Systems	\$ 595,344	\$ 564,313	5.5
Diabetes Care	249,272	240,483	3.7
Pharmaceutical Systems	79,013	72,351	9.2
Ophthalmic Systems	17,118	18,109	(5.5)
TOTAL	\$ 940,747	\$ 895,256	5.1
BD DIAGNOSTICS			
Preanalytical Systems	\$ 329,396	\$ 306,850	7.3
Diagnostic Systems	301,782	281,776	7.1
TOTAL	\$ 631,178	\$ 588,626	7.2
BD BIOSCIENCES			
Discovery Labware	\$ 74,233	\$ 71,399	4.0
Immunocytometry Systems	104,768	87,300	20.0
Clontech	23,163	24,353	(4.9)
Pharminggen	53,638	50,994	5.2
TOTAL	\$ 255,802	\$ 234,046	9.3
TOTAL UNITED STATES	\$1,827,727	\$1,717,928	6.4

</TABLE>

Page 10

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Nine Months Ended June 30, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

International					
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$ 552,210	\$ 492,978	12.0	2.6	9.4
Diabetes Care	181,814	150,008	21.2	9.0	12.2
Pharmaceutical Systems	292,773	262,048	11.7	(0.8)	12.5
Ophthalmic Systems	24,610	21,594	14.0	2.5	11.5
TOTAL	\$1,051,407	\$ 926,628	13.5	2.7	10.8
BD DIAGNOSTICS					
Preanalytical Systems	\$ 253,472	\$ 216,782	16.9	5.5	11.4
Diagnostic Systems	273,365	221,229	23.6	12.5	11.0
TOTAL	\$ 526,837	\$ 438,011	20.3	9.1	11.2
BD BIOSCIENCES					
Discovery Labware	\$ 66,953	\$ 60,511	10.6	(0.2)	10.8
Immunocytometry Systems	183,047	144,313	26.8	15.6	11.3
Clontech	22,911	24,501	(6.5)	(15.5)	9.0
Pharminggen	48,927	39,166	24.9	11.7	13.2
TOTAL	\$ 321,838	\$ 268,491	19.9	8.6	11.3

TOTAL INTERNATIONAL	\$1,900,082	\$1,633,130	16.3	5.4	11.0
---------------------	-------------	-------------	------	-----	------

</TABLE>

Page 11

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY BUSINESS SEGMENTS AND UNITS  
 Nine Months Ended June 30, (continued)  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

	Total				
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$1,147,554	\$1,057,291	8.5	4.1	4.4
Diabetes Care	431,086	390,491	10.4	5.7	4.7
Pharmaceutical Systems	371,786	334,399	11.2	1.4	9.8
Ophthalmic Systems	41,728	39,703	5.1	(1.1)	6.2
TOTAL	\$1,992,154	\$1,821,884	9.3	3.9	5.5
BD DIAGNOSTICS					
Preanalytical Systems	\$ 582,868	\$ 523,632	11.3	6.6	4.7
Diagnostic Systems	575,147	503,005	14.3	9.5	4.9
TOTAL	\$1,158,015	\$1,026,637	12.8	8.0	4.8
BD BIOSCIENCES					
Discovery Labware	\$ 141,186	\$ 131,910	7.0	2.1	5.0
Immunocytometry Systems	287,815	231,613	24.3	17.2	7.0
Clontech	46,074	48,854	(5.7)	(10.2)	4.5
Pharming	102,565	90,160	13.8	8.0	5.7
TOTAL	\$ 577,640	\$ 502,537	14.9	8.9	6.0
TOTAL REVENUES	\$3,727,809	\$3,351,058	11.2	5.9	5.3

</TABLE>

Page 12